UBS Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
– Sell
-29,200
Closed -$1.42M – 7931
2020
Q2
$1.42M Buy
+29,200
New +$1.4M ﹤0.01% 3200
2020
Q1
– Sell
-47,000
Closed -$2.01M – 7906
2019
Q4
$2.01M Buy
+47,000
New +$2.04M ﹤0.01% 3541
2016
Q1
– Sell
-2,900
Closed -$103K – 7574
2015
Q4
$103K Hold
2,900
– – ﹤0.01% 5177
2015
Q3
$96K Sell
2,900
-400
-12% -$16.6K ﹤0.01% 5267
2015
Q2
$138K Sell
3,300
-30,200
-90% -$1.17M ﹤0.01% 5163
2015
Q1
$1.09M Sell
33,500
-40,300
-55% -$1.39M ﹤0.01% 3491
2014
Q4
$2.34M Buy
+73,800
New +$2.09M ﹤0.01% 2752

Other funds holding ACAD

UBS Group's ACAD Position: Q3 2026 in Review

UBS Group increased its Acadia Pharmaceuticals (ACAD) stake by 60% in Q3 2026, buying an estimated $7.36M and bringing the position to 734,224 shares worth $14.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2991.

UBS Group first reported a position in ACAD in Q4 2014 and has held it in 48 quarters since. The position peaked at $22.8M in Q4 2024. 351 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • UBS Group held 734,224 shares of Acadia Pharmaceuticals worth $14.8M as of Q3 2026.
  • UBS Group bought 274,171 Acadia Pharmaceuticals shares in Q3 2026, an estimated $7.36M.
  • Acadia Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #2991 holding.
  • UBS Group first reported a position in Acadia Pharmaceuticals in Q4 2014 and has held it in 48 quarters since.
  • UBS Group's Acadia Pharmaceuticals position peaked at $22.8M in Q4 2024.
  • 351 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.